Coronavirus in Continuous Flux: From SARS-CoV to SARS-CoV-2

被引:15
作者
Dong, Yetian [1 ,2 ,3 ,4 ]
Dai, Tong [1 ,2 ]
Liu, Jun [5 ]
Zhang, Long [3 ,4 ]
Zhou, Fangfang [1 ,2 ]
机构
[1] Soochow Univ, Inst Biol, Suzhou 215123, Peoples R China
[2] Soochow Univ, Inst Med Sci, Suzhou 215123, Peoples R China
[3] Life Sci Inst, Hangzhou 310058, Zhejiang, Peoples R China
[4] Innovat Ctr Cell Signaling Network, Hangzhou 310058, Zhejiang, Peoples R China
[5] Pinghu Food & Drug Inspect Ctr, Pinghu 314200, Zhejiang, Peoples R China
关键词
biology; clinical symptoms; immune responses; SARS-CoV-2; therapeutic treatment; RESPIRATORY SYNDROME CORONAVIRUS; PAPAIN-LIKE PROTEASE; SPIKE PROTEIN; I INTERFERON; CLINICAL CHARACTERISTICS; CONVALESCENT PLASMA; CYTOKINE STORM; COVID-19; DOMAIN; VIRUS;
D O I
10.1002/advs.202001474
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The world is currently experiencing a global pandemic caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes severe respiratory disease similar to SARS. Previous studies have suggested that SARS-CoV-2 shares 79% and 96% sequence identity to SARS-CoV and to bat coronavirus RaTG13, respectively, at the whole-genome level. Furthermore, a series of studies have shown that SARS-CoV-2 induces clusters of severe respiratory illnesses (i.e., pneumonia, acute lung injury, acute respiratory distress syndrome) resembling SARS-CoV. Moreover, the pathological syndrome may, in part, be caused by cytokine storms and dysregulated immune responses. Thus, in this work the recent literature surrounding the biology, clinical manifestations, and immunology of SARS-CoV-2 is summarized, with the aim of aiding prevention, diagnosis, and treatment for SARS-CoV-2 infection.
引用
收藏
页数:18
相关论文
共 144 条
[1]  
Anderson D.E., 2020, BIORXIV
[2]  
[Anonymous], EFFICACY HYDROXYCHLO, DOI 10.1101/2020.03.22.20040758
[3]  
Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
[4]   Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model [J].
Beck, Bo Ram ;
Shin, Bonggun ;
Choi, Yoonjung ;
Park, Sungsoo ;
Kang, Keunsoo .
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2020, 18 :784-790
[5]  
Bian, 2020, MEPLAZUMAB TREATS CO, DOI 10.1101/2020.03.21.20040691
[6]   Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 [J].
Blanco-Melo, Daniel ;
Nilsson-Payant, Benjamin E. ;
Liu, Wen-Chun ;
Uhl, Skyler ;
Hoagland, Daisy ;
Moller, Rasmus ;
Jordan, Tristan X. ;
Oishi, Kohei ;
Panis, Maryline ;
Sachs, David ;
Wang, Taia T. ;
Schwartz, Robert E. ;
Lim, Jean K. ;
Albrecht, Randy A. ;
tenOever, Benjamin R. .
CELL, 2020, 181 (05) :1036-+
[7]   Severe acute respiratory syndrome coroavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides [J].
Bosch, BJ ;
Martina, BEE ;
van der Zee, R ;
Lepault, J ;
Haijema, BJ ;
Versluis, C ;
Heck, AJR ;
de Groot, R ;
Osterhaus, ADME ;
Rottier, PJM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (22) :8455-8460
[8]   Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2 [J].
Cai, Guoshuai ;
Bosse, Yohan ;
Xiao, Feifei ;
Kheradmand, Farrah ;
Amos, Christopher I. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201 (12) :1557-1559
[9]  
Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI [10.1056/NEJMoa2001282, 10.1056/NEJMc2008043]
[10]   COVID-19: immunopathology and its implications for therapy [J].
Cao, Xuetao .
NATURE REVIEWS IMMUNOLOGY, 2020, 20 (05) :269-270